Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

January 2026 Biohacking Index Report Introduces an Invite-Only Expert Model Ready to Announce with Confidence?

newsfilecorp.com

January 2026 Biohacking Index Report Introduces an Invite-Only Expert Model Ready to Announce with Confidence? New York, New York--(Newsfile Corp. - February 4, 2026) - The January 2026 Report represents the first physician-curated, invite-only edition of the Biohacking Index report, reinforcing the platform's core principle that credibility, not sponsorship or popularity, should determine visibility in the wellness and biohacking ecosystem.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

Click image above to view full announcement.

About Wellness Eternal

Wellness Eternal is a data driven health education company dedicated to advancing truth, safety, and efficacy in wellness and biohacking. Through research, verified ratings, and media amplification, Wellness Eternal helps individuals and practitioners make informed decisions about emerging health solutions.

About the Biohacking Index

The Biohacking Index is a verified ratings and reviews platform focused on biohacking, longevity, and human performance. It exists to bring clarity, credibility, and accountability to one of the fastest growing areas of health and wellness by elevating the companies that consistently deliver real world results.

Contacts:

Wellness Eternal Communications

914-846-9444

we@wellnesseternal.com

Source: Newsworthy.ai

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282669

Source: Reportable, Inc.

Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Reportable, Inc. or all companies in the Multimedia / Internet / Online Services industry.

Stonegate Capital Partners Updates Coverage On Surf Air Mobility Inc. (SRFM) Q425

2026-03-13 4:37 PM EDT

Stonegate Capital Partners Updates Coverage on Aquafil Group (ECNL) Q425

2026-03-13 1:12 PM EDT

Glafabra Therapeutics Receives FDA Orphan Drug Designation for GT-GLA-S03, Advancing a Redosable Cell Therapy for Fabry Disease

2026-03-12 10:04 AM EDT

Dec 01, 2025

The year-end sprint is on. For your Investor Relations team, the time between now and the end of Q1 2026 will be packed with financial reporting, proxy statements, and regulatory filings.

Multimedia / Internet / Online Services